<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499953</url>
  </required_header>
  <id_info>
    <org_study_id>SURPRISE-2011</org_study_id>
    <nct_id>NCT01499953</nct_id>
  </id_info>
  <brief_title>Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux</brief_title>
  <official_title>Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus&#xD;
      fondaparinux in the treatment of superficial vein thrombosis (SVT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of efficacy and safety of 45 days of rivaroxaban 10 mg vs. fondaparinux 2.5 mg in&#xD;
      the treatment of superficial vein thrombosis of risk patients for major VTE complications to&#xD;
      prove non-inferiority of oral rivaroxaban treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composit-Endpoint VTE</measure>
    <time_frame>45 +/- 5 days</time_frame>
    <description>Composite of&#xD;
death from any cause&#xD;
symptomatic pulmonary embolism&#xD;
symptomatic deep vein thrombosis&#xD;
symptomatic extension towards the saphenofemoral junction&#xD;
symptomatic recurrence of superficial vein thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite primary efficacy outcome</measure>
    <time_frame>90 +/- 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>each component of primary efficacy outcome up to day 45 and day 90</measure>
    <time_frame>90 +/-10 days</time_frame>
    <description>symptomatic pulmonary embolism&#xD;
symptomatic deep vein thrombosis&#xD;
symptomatic extension towards the saphenofemoral junction&#xD;
symptomatic recurrence of superficial vein thrombosis&#xD;
death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of major VTE</measure>
    <time_frame>90 +/-10 days</time_frame>
    <description>composite of:&#xD;
symptomatic pulmonary embolism&#xD;
symptomatic proximal DVT&#xD;
VTE-related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rates of surgery for SVT</measure>
    <time_frame>90 +/-10 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding (Main safety outcome)</measure>
    <time_frame>45 +/- 5 days</time_frame>
    <description>associated with a fall of hemoglobin of 2 g/l or more, or;&#xD;
leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or;&#xD;
occurring into a critical site such as intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or;&#xD;
fatal bleeding.</description>
  </other_outcome>
  <other_outcome>
    <measure>clinically relevant non-major, minor and total (any) bleeding</measure>
    <time_frame>45 +/- 5 days</time_frame>
    <description>Clinically relevant, non-major bleeding is defined as any overt bleeding and&#xD;
associated with a medical intervention, or&#xD;
unscheduled contact with the physician (presence or telephone contact)&#xD;
temporary or complete cessation of study drug&#xD;
associated with any relevant discomfort to the patient (pain, impairment of activities of daily life)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">472</enrollment>
  <condition>Superficial Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban for 45 days oral dose: 10 mg OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondaparinux</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fondaparinux for 45 days subcutaneous application: 2,5 mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <description>Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous</description>
    <arm_group_label>Fondaparinux</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute symptomatic supragenual superficial vein thrombosis of the leg&#xD;
&#xD;
          -  at least one of the following major risk factor for VTE:&#xD;
&#xD;
          -  age &gt; 65 years or&#xD;
&#xD;
          -  male sex or&#xD;
&#xD;
          -  history of DVT/PE/SVT or&#xD;
&#xD;
          -  history of cancer or active cancer or&#xD;
&#xD;
          -  autoimmune disease or&#xD;
&#xD;
          -  SVT of a non-varicose vein&#xD;
&#xD;
          -  thrombus extension of at least 5 cm&#xD;
&#xD;
          -  proximal thrombus end with more than 3 cm distance to the saphenofemoral junction&#xD;
             (SFJ)&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other indication for therapeutic anticoagulation such as acute deep vein thrombosis,&#xD;
             acute pulmonary embolism, atrial fibrillation with indication for anticoagulant&#xD;
             therapy&#xD;
&#xD;
          -  any PE or DVT within last 6 months before inclusion&#xD;
&#xD;
          -  clinical signs of PE without objective exclusion (CT or VQ scan, angiography)&#xD;
&#xD;
          -  SVT without signs of thrombotic/inflammatory activity (activity signs: diameter &gt; 4&#xD;
             mm, pain, redness, elevated local or systemic temperature)&#xD;
&#xD;
          -  SVT after sclerotherapy&#xD;
&#xD;
          -  Duration of symptoms &gt; 3 weeks&#xD;
&#xD;
          -  pretreatment of more than 72 h with therapeutic dosages of oral or parenteral&#xD;
             anticoagulants&#xD;
&#xD;
          -  pretreatment of more than 5 days with subtherapeutic oral or parenteral anticoagulants&#xD;
&#xD;
          -  indication for escalated antiplatelet therapy (monotherapy with aspirin &gt; 325 g/d and&#xD;
             any dual antiplatelet therapy)&#xD;
&#xD;
          -  SVT closer than 3 cm to saphenofemoral junction (SVJ)&#xD;
&#xD;
          -  anticipated superficial vein surgery within 90 days&#xD;
&#xD;
          -  anticipated thrombolytic therapy within 90 days&#xD;
&#xD;
          -  manifest clinically relevant bleeding&#xD;
&#xD;
          -  clinically relevant bleeding in the last 30 days before study inclusion&#xD;
&#xD;
          -  major surgery within last 30 days before inclusion&#xD;
&#xD;
          -  ophthalmic, spinal or cerebral surgery within last 90 days&#xD;
&#xD;
          -  severe head trauma within last 90 days&#xD;
&#xD;
          -  hemorrhagic stroke within last 12 months&#xD;
&#xD;
          -  hereditary or acquired severe hemorrhagic diathesis&#xD;
&#xD;
          -  gastrointestinal bleeding within last 90 days requiring endoscopy&#xD;
&#xD;
          -  uncontrolled arterial hypertension (systolic &gt; 180 mm Hg, diastolic &gt; 110 mm Hg)&#xD;
&#xD;
          -  acute endocarditis&#xD;
&#xD;
          -  low platelet count (&lt; 100 x 109/l)&#xD;
&#xD;
          -  Prothrombin time &lt; 50 %&#xD;
&#xD;
          -  calculated creatinine clearance &lt; 30 ml/min&#xD;
&#xD;
          -  significant liver disease such as acute hepatitis, chronic active hepatitis, cirrhosis&#xD;
&#xD;
          -  life expectancy &lt; 3 months&#xD;
&#xD;
          -  any contraindications listed for rivaroxaban or fondaparinux&#xD;
&#xD;
          -  women of child bearing potential without safe contraception method&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  participation in another trial with pharmacological intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Beyer-Westendorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>on behalf of GWT-TUD GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hautarztpraxis</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Mietaschk, Bilderling, Kaiser, Tato</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chriurgische Praxisklinik</name>
      <address>
        <city>Baesweiler</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oberlausitz-Gefäßpraxis</name>
      <address>
        <city>Görlitz</city>
        <state>Sachsen</state>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Ramdohr, Praxis für Cardiovaskulär- u. Ultraschalldiagnostik</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Chirurgie &amp; Gefäßmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt GmbH</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Eggeling und Winter</name>
      <address>
        <city>Eschwege</city>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Westklinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxisgemeinschaft</name>
      <address>
        <city>Hoppegarten</city>
        <zip>15366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademie für Gefäßkrankheiten e.V.</name>
      <address>
        <city>Karlsbach</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Allgemeinmedizin und Phlebologie</name>
      <address>
        <city>Köln</city>
        <zip>50670</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR Innere Medizin - Angiologische Ambulanz</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Franke</name>
      <address>
        <city>Magdeburg</city>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologie Mühldorf am Inn</name>
      <address>
        <city>Mühldorf am Inn</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kähler</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Gefäßmedizin am Tegernsee</name>
      <address>
        <city>Rottach-Egern</city>
        <zip>83700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venenzentrum Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65183</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>superficial vein thrombosis</keyword>
  <keyword>thrombosis</keyword>
  <keyword>SVT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 21, 2018</submitted>
    <returned>October 25, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

